These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Seagen Inc.

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for HER2-positive breast cancer. Each event will employ an identical format that will include the following elements:

• Moderator Dr Neil Love and a featured participating clinical investigator
• Discussion of participating faculty treatment recommendations
• Review of available clinical research findings
• Community oncologist video case presentations
• Interactive audience polling and extensive Q&A

MODULE 1: Optimal Management of HER2-Positive Localized Breast Cancer

MODULE 2: Evolving Treatment Paradigm for HER2-Positive and HER2-Low Metastatic Disease

MODULE 3: Treatment Approaches for Patients with HER2-Positive Breast Cancer and Brain Metastases

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of breast cancer.

Learning Objectives

• Consider available research data to individualize the selection of neoadjuvant, adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
• Implement a long-term clinical plan for the management of advanced HER2-positive breast cancer considering recently presented clinical research findings and incorporating available and recently approved targeted agents and regimens.
• Design an optimal approach to the care of patients with HER2-positive breast cancer and CNS metastases, evaluating the implications of prior therapeutic exposure, symptomatology and other factors.
• Appreciate the incidence, pathologic and molecular characteristics of HER2-low metastatic breast cancer, and understand currently available management approaches for this disease subset.
• Recognize common and rare side effects associated with existing and recently approved anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive breast cancer.
• Assess ongoing clinical research evaluating novel agents and treatment strategies under development for HER2-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Carey has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Lin — Consulting Agreements: Affinia Therapeutics, Aleta Biotherapeutics, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Daiichi Sankyo Inc, Denali Therapeutics, Janssen Biotech Inc, Olema Oncology, Prelude Therapeutics, Puma Biotechnology Inc, Seagen Inc, Voyager Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Merck, Olema Oncology, Pfizer Inc, Seagen Inc, Zion Pharmaceuticals. Dr Pegram — Advisory Committee: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Halozyme Inc, Pfizer Inc, Sanofi, Seagen Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Biotheranostics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Halozyme Inc, Seagen Inc; Contracted Research: Pfizer Inc; Data and Safety Monitoring Board/Committee: Roche Laboratories Inc; Nonrelevant Financial Relationship: Spouse employed by Rain Therapeutics Inc.

SURVEY PARTICIPANTS — Adam M Brufsky, MD, PhD — Consulting Agreements: Agendia Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Lilly, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Sanofi, Seagen Inc; Contracted Research: Agendia Inc, AstraZeneca Pharmaceuticals LP. Professor Giuseppe Curigliano, MD, PhD — Advisory Committee: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Novartis, Pfizer Inc; Consulting Agreement: Menarini Group; Data and Safety Monitoring Board/Committee: Novartis; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Pfizer Inc. Joyce O’Shaughnessy, MD — Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Halozyme Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Myriad Genetic Laboratories Inc, Nektar, Novartis, Ontada, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi, Seagen Inc, Syndax Pharmaceuticals Inc, Synthon, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Lilly, Pfizer Inc, Seagen Inc.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Seagen Inc.